title: Low-grade Nonrhabdomyosarcoma Soft Tissue Sarcoma: What is Peculiar for Childhood.
abstract: Nearly half of soft tissue sarcomas are nonrhabdomyosarcomas (NRSTSs). The low-grade (LG) form comprises a heterogenous group of diseases that rarely metastasize but are known for local recurrence.
  
  
  
  The aim of the study was to retrospectively evaluate pediatric LG-NRSTS with regard to demography, survival, and factors affecting outcome in Egyptian patients.
  
  
  
  The study reviewed 66 NRSTS patients who presented to the Pediatric Oncology Department, National Cancer Institute, Cairo University, between January 2008 and December 2013.
  
  
  
  Out of the reviewed cases 32 patients had LG tumors and were eligible for analysis. The male to female ratio was 1:1 and the median age was 7.5 years (range, 1 mo to 18 y). Desmoid fibromatosis (N=18) showed frequent local recurrence and nearly half of this group was alive without disease. No recurrence of the disease occurred in the nonfibromatosis group (n=14) and all patients were alive and free of disease. The 5-year overall survival was 88% for the entire group of study patients versus 45% for event-free survival. Tumors >5 cm in diameter and fibromatosis histology subtype were associated with lower EFS.
  
  
  
  LG-NRSTS generally has good prognosis, with overall survival reaching 90%. However, aggressive fibromatosis usually runs a poorer course in the form of high incidence of local recurrence and lower survival rates. This needs to be further assessed in larger prospective studies including novel therapies in addition to the current conventional modalities.
authors.affiliation: Departments of *Pediatric Oncology §Surgical Oncology, National Cancer Institute, Cairo University †Department of Pediatric Oncology, Children Cancer Hospital ‡Department of Pediatrics, National Research Center ∥Department of Pediatrics, Misr Insurance Hospital, Cairo, Egypt.
authors.forename: Mohamed
authors.initials: M
authors.lastname: Fawzy
authors.forename: Mohamed
authors.initials: M
authors.lastname: Sedky
authors.forename: Hossam
authors.initials: H
authors.lastname: ElZomor
authors.forename: Magdy
authors.initials: M
authors.lastname: El Sherbiny
authors.forename: Emad
authors.initials: E
authors.lastname: Salama
authors.forename: Ahmed
authors.initials: A
authors.lastname: Mahdy
mesh_terms: D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D004534:Egypt; D005260:Female; D005350:Fibroma / Q000473:pathology; D006801:Humans; D007223:Infant; D008297:Male; D009364:Neoplasm Recurrence, Local; D011379:Prognosis; D012189:Retrospective Studies; D012509:Sarcoma / Q000000981:diagnostic imaging / Q000401:mortality* / Q000473:pathology / Q000628:therapy*; D015996:Survival Rate